Diabetes Actual

Price Per License
Expected License Value
198,900 of 500,000
Licenses available
For a larger allocation, please contact us
Earnings Calculator
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Diabetes Actual seeks to restore metabolic wellness through the use of proven therapies for reversing the ravages of diabetes by restoring insulin sensitivity. This is made possible through a partnership with the US-based company, Well Cell Global, as we deploy their FDA-approved, life-saving technology throughout the world.

With over 7,000 patients treated across 35 US clinics and 5 international treatment centers, their patented technology promotes cell health and organ revitalization, using a safe method that has evolved over the last 70 years of scientific progress. By focusing on the body as a whole, Diabetes Actual can increase overall health by restoring metabolic wellness. The key is regaining insulin sensitivity and is based on restoring the normal rhythmic release of insulin.

Physiology 101: Every cell in the body has insulin receptors on their surface and, depending on the type of cell, they function differently in response to insulin signals. Too much insulin stimulates many unwanted effects on cells and their function. For instance, too much insulin leads to the deposition of fat into the abdominal cavity (visceral fat), liver and pancreas which causes inflammation. Inflammation leads to atherosclerosis, hypercholesterolemia and hypertension and is a major factor in the development of cancer. Patients can suffer from stroke and heart attack, kidney failure, vision problems, erectile dysfunction and neuropathy and are more susceptible to breast, prostate, colon and pancreatic cancer to name a few. To varying degrees all of the cells in a diabetic body are subject to the cocktail of too much insulin, too much glucose and toxic inflammatory molecules.

Get Rhythm: The insulin signals are designed to operate every six to eight minutes. This insulin cycle allows each cell in the body to respond to insulin, take up glucose, generate maximal energy and recycle their insulin receptor for another round. Individual cells cannot respond efficiently to a constant unrelenting insulin signal. The result is a decrease in cell metabolic function and eventual organ dysfunction.

PILLS, pills and more pills: Current treatments are focused on symptom suppression and tight glucose control which has not led to significant improvement in survival nor the prevention or improvement in diabetic complications. Patients who develop problems with blood pressure, cholesterol, nerve pain, erectile dysfunction, kidney problems, vision impairment and non-healing wounds are treated with another pill and admonished to eat less and exercise while their diabetic medications continue to increase. Little progress has been made and diabetes contributes directly to 6 of the top 10 causes of death in the US. (Heart Disease, Cancer, Stroke, Alzheimer’s, Diabetes, Kidney Failure)

Diabetes Actual uses Physiologic Insulin Re-Sensitization (PIR) protocols, which is a novel approach based on the healthy innate reciprocal pulsatile release of insulin from the pancreas. Diabetic patients are treated in two to three hour sessions on a weekly basis with tightly controlled, timed insulin intravenous infusions given by precision pumps. Most patients require 10 sessions over several months to restore their insulin sensitivity and regular maintenance sessions Diabetes Actual does not offer a definitive cure for diabetes but restores function and reverses many of the symptoms of Diabetes. Patients can then benefit from the full array of metabolism boosters and life style and dietary changes that Diabetes Actual provides to attain and sustain maximal metabolic wellness.

This metabolic wellness life is available for a wide array of patients, with or without diabetes, and we have seen it help with wound healing, Parkinson’s disease, aging and aesthetic issues. Patients have overwhelmingly reported increased energy, restful sleep, weight loss, decreased neuropathy pain, reduced medications and lower Hemoglobin A1C as a result of PIR protocols that can control and reverse insulin resistance.

Diabetes is the most expensive medical condition in the USA. Eventually, oral medications may not be enough to keep blood glucose levels normal. Adding insulin to get blood glucose levels to a healthy level is a sign of worsening disease. In a patient with insulin resistance the toxic effects of additional insulin only exacerbates the deleterious effects of high levels of insulin and portends an increased velocity to the disease spiral of worsening complications. Many believe that Type 2 Diabetes is a chronic and progressive disease. The reality is that for most, it doesn’t need to be progressive and there is hope for symptom resolution and or stabilization.

MetabolicWellness.life: Diabetes Actual’s pulsatile insulin protocol restores insulin sensitivity to cells, helping to ensure that maximal energy is generated. What sets Diabetes Actual apart is our combination of additional clinical therapies alongside the PIR protocols. This includes intermittent fasting, hormone replacement therapy and exercise with a goal of increasing patients’ metabolic health.

Diabetes Actual is a MariamTek brand and we are licensing partnerships with regional distributors in the US, the Asia Pacific and GCC countries. With a launch in the USA Midwest underway, and an imminent plan to launch a new PIR training facility in the GCC and/or India, Diabetes Actual is set to become a leading player in diabetes treatment globally.

Revenue Streams

Diabetes Actual wants to get as many diabetics as possible treated as soon as possible and we know that we cannot build enough Diabetes Actual clinics to provide this care. This technology needs to be available for all of the leading clinical providers who want a new tool to assist their diabetic patients.

In addition to a Diabetes Actual Franchise model, Diabetes Actual banks revenue on commission for license sales, and revenue for training local providers on the correct use of the protocols. This will be profitable for Diabetes Actual at each step of the treatment cycle.

Our ILO entitles buyers to 10% of our total revenue, divided evenly amongst all ILO holders. You can buy our ILO for just $4 per license to help revolutionize the treatment of diabetes, and make money while doing it.

Dr Holterman is the founder of the Mariam Group which is a philanthropic organization dedicated to improving life on the planet with solutions to the most vexing problems affecting health, habitat and human development. MariamTek is the for-profit operational arm, which finds and develops transformative and far-reaching solutions on a global scale.

His experience as a practicing physician-surgeon and research scientist enables him to identify and verify solutions to a variety of problems, particularly in the healthcare field. When it comes to Diabetes Actual, Dr Holterman deploys the same technologies in his own clinic with good success and happy patients.

Trupti Parikh is a pediatric nurse practitioner with 20 years of experience in healthcare, including direct patient nursing and administration. She is dedicated to the mission of global health and the goal of healthy functional aging, and currently serves as the Director of Clinical Development for Diabetes Actual.

Ravindra is a serial entrepreneur specializing in IT and education is based in India and the UAE. He is a partner and founding member of MariamTek and the Mariam Group. He brings his business experience and global connectivity to the development and deployment of Diabetes Actual protocols to the world.

Looking for more information? Get in touch with Diabetes Actual


Our ILO guarantees that when we make money - you make money.

ILO’s are not based on profits, but gross revenue, or all sales without any costs or taxes subtracted, therefore if you buy our ILO you will make money as we make sales.

These projections are provided by us, MARIAMTEK, INC.. If you agree they are realistic and achievable, buy our ILO today.

November 29, 2021

Commencement Date


Licenses Available


Current Allocation


Total Issued



per license, 10% royalty in year 1


per license, 10% royalty in year 2


per license, 10% royalty in year 3

Projected Revenue

Year 1
Year 2
Year 3

Projected License Value

Year 1
Year 2
Year 3

In addition to paying you a royalty, at the end of the 3rd year MARIAMTEK, INC. can choose to extend the license for another 3 years, or buy the ILO back for cash should MARIAMTEK, INC. conduct a major financing.

ILO Value is the estimated value of your ILO in USD ($). This is calculated using our projected revenue numbers. Therefore if our revenue projections are realistic and achievable, this is a good estimation of the buy out price you should expect at different stages.

Looking for more information? Get in touch with Diabetes Actual

Help & Feedback

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
2s560 Maple Terrace Warrenville, IL 60555 USA

ILO Standard License

THIS AGREEMENT is between MARIAMTEK, INC. (“the Company”), - AND – The Buyer who is the Current License Holder as determined by the Live Ledger held by ILOCX which holds details of licenses issued bought and sold (“the Buyer”).

This license commences on:

November 29, 2021

Details of the Licensed Product are described on the Company’s page hosted on the site at www.ILOCX.com

Special Conditions:


Minimum Requirements for Qualification are a confirmed share of the Company’s information and Promotional Message on social media. This can be done on the ILOCX platform. Alternative ways to qualify are at the discretion of the company selling the license.

Initial price per license:


Under the License Agreement the buyer is entitled to royalty payments once qualified

Each License receives a royalty equal to 10% of the Gross Revenues from the recorded and officially filed revenue, divided by 500,000, the total amount of ILO Units in the Initial License Offering. All royalties will be paid to the Buyer’s wallet on the ILOCX platform within 5 days of payment settlement from the company. These days will be announced prior to release.

This License is for an Initial Term of 3 years at which time the License can be extended by the issuing Company for a further 3 years, (a “Rollover”) and new terms may be set by the company at this time in line with ILOCX exchange rules and guidelines. Alternatively, the Company may offer to buy the License back from the Buyer (“a ‘Buyback”). The Company will give notice of Rollover terms or Buyback Price 90 days before the end of the Initial Term, as outlined in the Buyer Terms and Conditions.

All licenses must be valid and deemed qualified to benefit from the Royalty and the Rollover or Buyback.

This Agreement should be read in conjunction with the License Terms and Conditions, the Company Terms and Conditions, the Buyer Terms and Conditions and the ILOCX Terms of Use which form part of this entire Agreement, as well all ILOCX rules, policies, rulings and procedural requirements (collectively the “ILOCX Terms and Conditions”).

All parties have read and agreed to comply with the ILOCX Terms and Conditions, this Agreement, and any documents included by reference above. These may be amended from time to time and the parties will be notified by email of such amendments. Breach of any of the terms of this agreement may result in termination of this Agreement under the termination procedures outlined in the License Terms and Conditions.

This Agreement shall be governed by the laws of England and Wales and the parties exclusively submit to the jurisdiction of the Courts of England and Wales. In the event of any dispute, refer to the terms and conditions for the procedure.

Agreed on behalf of the Company:
The Company confirms its consent to this License Agreement by presenting the ILO for sale on the ILOCX platform.

Agreed on behalf of the Buyer:
The Buyer consents to this agreement by completing their order on ILOCX.

Looking for more information? Get in touch with Diabetes Actual

December 1, 2021
Diabetes Actual Lists on ILOCX

Diabetes Actual seeks to restore metabolic wellness through the use of proven therapies for reversing the ravages of diabetes by restoring insulin sensitivity.

This revolutionary technology needs to be available to all leading clinical providers. The ILO will open Diabetes Actual up to a broad network of supporters, who can help achieve our goal of treating as many diabetics as possible, as soon as possible.

Price Per License
Expected Value Year 3
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Projected ILO Earnings

License Value
Create Account
Fill the information below to sign in to your account

We will send you a link to verify your email and set your password.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Sign In
Fill the information below to sign in to your account
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Forgot Password
Enter your registered email and we’ll send you reset password instruction

Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Projected Royalties
We are commited to distribute 10% of revenue received by Blue Sky Solar evenly amongst qualified license holders. These are our projected total royalty payments: